NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00412022,"HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer.",https://clinicaltrials.gov/study/NCT00412022,HOBOE,UNKNOWN,"The HOBOE study was amended in November 2009, and, after reaching enrollment of the first 500 patients, the study began recruiting premenopausal patients only. The primary objective of the extended study is to compare disease free survival in premenopausal patients with early breast cancer. Patients receive triptorelin and are randomized in a 1:1:1 fashion to receive tamoxifen or letrozole, or letrozole + zoledronic acid.

The purpose of the HOBOE study, Version 1, was to compare the adjuvant hormonal therapy treatments of Tamoxifen, Letrozole and Letrozole + Zoledronate for their effects on bone loss in breast cancer patients. Postmenopausal and premenopausal patients were eligible, the latter also receiving monthly triptorelin. Upon reaching the enrollment of the first 500 patients in March 2010, the study began recruiting premenopausal patients only.",NO,Breast Cancer,DRUG: tamoxifen|DRUG: triptorelin|DRUG: letrozole|DRUG: zoledronic acid,"disease free survival in premenopausal patients, observation period is 10 years from initiation of treatment|bone mineral density, 12 months from initiation of therapy","Bone mineral density measured, yearly after first year of therapy|disease free survival in postmenopausal patients, observation period is 10 years from initiation of treatment|overall survival, observation period is 10 years from initiation of treatment|toxicity of letrozole + triptorelin and letrozole + zoledronic acid + triptorelin in premenopausal patients, monthly",,"National Cancer Institute, Naples",University of Campania Luigi Vanvitelli,FEMALE,"ADULT, OLDER_ADULT",PHASE3,1294,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,HOBOE,2004-03,2024-11,2024-11,2006-12-15,,2023-03-24,"S. Giuseppe Moscati, Avellino, AV, Italy|Azienda Ospedaliera Treviglio - Caravaggio, Treviglio, BG, Italy|Azienda Ospedaliera G. Rummo, Benevento, BN, Italy|Ospedale Senatore Antonio Perrino, Brindisi, BR, Italy|Istituto Romagnolo per lo Studio e la Cura dei Tumori, Meldola, FC, Italy|Presidio Ospedaliero Di Saronno Aziendo Ospedaliera di Busto Arsizio, Saronno, VA, Italy|Ospedale Santa Maria Annunziata, Bagno a Ripoli, Italy|Istituto Nazionale per la ricerca Sul Cancro, Genova, Italy|Ospedale Riuniti, Livorno, Italy|Ospedale Unico della Versilia, Lucca, Italy|Istituto Nazionale dei Tumori,, Napoli, Italy|Ospedale Cardarelli, Napoli, Italy|Seconda Università di Napoli, Napoli, Italy|Università Federico II, Cattedra di Oncologia Medica, Napoli, Italy|Casa di Cura La Maddalena, Palermo, Italy|Ospedale Silvestrini, Perugia, Italy|Ospedale Santa Chiara, Pisa, Italy|Università di Sassari, Sassari, Italy|Ospedale Santa Chiara, Trento, Italy|ASL Viterbo Ospedale Belcolle, Viterbo, Italy",
